Lh-type bispecific antibody
AssigneeTohoku University
InventorsIzumi KUMAGAI, Ryutaro ASANO, Mitsuo UMETSU
Life of this patent
Estimating the term…
Loading patent…
AssigneeTohoku University
InventorsIzumi KUMAGAI, Ryutaro ASANO, Mitsuo UMETSU
Estimating the term…
Provided are a novel diabody type bispecific antibody, the function of which as a bispecific antibody is improved to provide a higher additional value, such as cost saving caused by a reduction in dose, to a drug; and a method for producing the same. A humanized diabody type bispecific antibody (LH-diabody type bispecific antibody) characterized in that an L-chain is located in the N-terminal side in each polypeptide (LH type); a humanized high-functional bispecific antibody which contains said LH diabody type bispecific antibody; a nucleic acid molecule encoding both of two kinds of single-stranded polypeptides constituting said bispecific antibody; and a method for producing said antibody which comprises culturing a host cell having been transformed by an expression vector containing said nucleic acid molecule.
A nucleic acid molecule encoding the single-chain polypeptide constituting the diabody-type bispecific antibody consisting of a first polypeptide comprising a humanized variable region of the light chain (5L) of an anti-human EGF receptor 1 antibody 528 and a humanized variable region of the heavy chain (OH) of an anti-CD3 antibody OKT in this order from its N-end to C-end;
A method for the production of a humanized diabody-type bispecific antibody consisting of two kinds of the single-chain polypeptides of (5L OH) and (OL5H) or a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3;
A method for the production of a humanized diabody-type bispecific antibody consisting of two kinds of the single-chain polypeptides of (5L OH) and (OL5H) or a humanized highly functional bispecific antibody comprising humanized variable regions of the heavy chain (5H) and the light chain (5L) of an anti-human EGF receptor 1 antibody 528, and humanized variable regions of the heavy chain (OH) and the light chain (OL) of an anti-CD3 antibody OKT3;
Dependencies are inferred from the claim text.